Colchicine is a potent anti-inflammatory agent (non-immunosuppressive!) with multiple mechanisms of action on the innate immune system and neutrophils. The indications for colchicine are rapidly increasing, with one study showing that low-dose colchicine substantially decreased ischemic cardiovascular events among patients who recently underwent a myocardial infarction (*N Engl J Med* 2019;381:2497-505). This study led some to dub colchicine as the "new aspirin" (Could colchicine be the new aspirin? <https://www.medscape.com/viewarticle/923819>). There is a large trial underway to treat/prevent the hyperinflammation associated with COVID-19. However, colchicine is potentially fatal when overdosed, with a narrow margin of safety between effective and toxic doses, including bone marrow suppression. Therefore, it is important to study its safety profile.

The main indication of colchicine in children is for familial Mediterranean fever (FMF) in which colchicine needs to be taken lifelong. First discovered as effective for FMF in 1972, the safety profile of colchicine appeared to be excellent, but there are very few reports on the issue of leukopenia. A study by Sag et al reported in this volume of *The Journal* regarding the prevalence and significance of leukopenia was not systemically studied in a prospective cohort. They found an 11% prevalence of leukopenia unexplained by other causes among 213 consecutive children with FMF treated with age-based standard doses of colchicine. None of the patients had severe leukopenia/neutropenia and infection rates were not increased among these patients. Leukopenia resolved after dose adjustments. Although we periodically need to monitor white cell counts in these patients, the results of this study add another layer to the known safety profile of colchicine and should be reassuring to physicians and the increasing number of patients using this medication.FigureColchicine doses were comparable in patients with or without leukopenia at the time of leukopenia onset. Adjusted doses were significantly lower. \**P* \< .05, \*\**P* \< .01.
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